Effectiveness of Maternal Immunization With Boostrix at Preventing Pertussis Among Infants <2 Months Old in the United States

Pertussis Vaccination in Pregnant Women

NCT03909126 ·Status: COMPLETED ·Phase: PHASE4

Safety and Immunogenicity of 2 Doses Versus 1 Dose of Acellular Pertussis Vaccines Containing Genetically-detoxified Pertussis Toxin in Young Adults Previously Primed With Acellular Pertussis Vaccines

NCT05193734 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3

Pertussis (Tdap) Vaccination in Pregnancy

NCT01698346 ·Status: COMPLETED ·Phase: PHASE4

Vaccine Responses in Infants After Acellular Pertussis Vaccination During Pregnancy in Thailand

NCT02408926 ·Status: COMPLETED ·Phase: PHASE4

Maternal Determinants of Infant Immunity to Pertussis

NCT05856396 ·Status: COMPLETED ·Phase: PHASE4

Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery

NCT02853929 ·Status: COMPLETED ·Phase: PHASE4

First Adult Safety Trial on Nasal Live Attenuated B. Pertussis Vaccine

NCT01188512 ·Status: COMPLETED ·Phase: PHASE1

Viaskin Pertussis Vaccine Trial

NCT03035370 ·Status: COMPLETED ·Phase: PHASE1

A Study of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Diphtheria, Pertussis and Tetanus (Tdap) Viruses Followed by a 2nd Dose of the RSV Vaccine to Healthy Non-Pregnant Women

NCT04138056 ·Status: COMPLETED ·Phase: PHASE2

Gambia Pertussis Study (GaPs)

NCT03606096 ·Status: UNKNOWN ·Phase: PHASE4

Rates of Pertussis Disease Among Persons Receiving Pentacel® or Other Pertussis Vaccines

NCT01129362 ·Status: COMPLETED

Pediatric Pertussis in Ambulatory Settings

NCT04807712 ·Status: RECRUITING

Post-marketing Surveillance to Assess the Safety of Boostrix Vaccine Given According to Prescribing Information in Korea

NCT01929291 ·Status: COMPLETED

The Optimal Timing of Vaccination in Pregnancy

NCT06466629 ·Status: RECRUITING

Immunogenicity and Safety of GSK Biologicals' Boostrix Polio Vaccine in 3 and 4-year-old Children

NCT01245049 ·Status: COMPLETED ·Phase: PHASE3

Knowledge of Pregnant Women Concerning Pertussis, Vaccination Against Pertussis and Cocooning Strategy

NCT06114160 ·Status: NOT_YET_RECRUITING

A Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK)'s Infanrix Hexa Vaccine (DTPa-HBV-IPV/Hib) Versus MCM Vaccine BV's Vaxelis Vaccine (DTaP5-HBV-IPV-Hib) in Healthy Infants and Toddlers

NCT04535037 ·Status: COMPLETED ·Phase: PHASE4

Study of a New Formulation of DTPa-HBV-IPV/Hib Vaccine Administered as a Booster Dose to 18-23 Months Old Children

NCT00611559 ·Status: COMPLETED ·Phase: PHASE4

Assess Feasibility of an Acellular Pertussis Vaccine (Pa) Given Soon After Birth, Followed by 3-dose Primary Vaccination With the DTPa-HBV-IPV/Hib Vaccine

NCT00289796 ·Status: COMPLETED ·Phase: PHASE2

Study of a Birth Dose of GlaxoSmithKline Biologicals' 251154 Vaccine

NCT01110044 ·Status: WITHDRAWN ·Phase: PHASE2

Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery

NCT02422264 ·Status: COMPLETED ·Phase: PHASE4

Immunogenicity and Safety of a Booster Dose of Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Hib Vaccine in 365-569 Days Old Healthy Infants

NCT01226953 ·Status: COMPLETED ·Phase: PHASE3

Long-term Persistence Study to Assess a Booster Dose of GSK Biologicals' Hib-MenC

NCT00322335 ·Status: COMPLETED ·Phase: PHASE3

A Study of the Immunogenicity and Safety of Whole-Cell Pertussis Containing Vaccine Administered Concomitantly With RotaTeq™ (V260) or Rotarix™ (V260-036)(WITHDRAWN)

NCT01003431 ·Status: WITHDRAWN ·Phase: PHASE3

Study to Asses DTPw-HBV/Hib at 15-18 Months (m) and Mencevax™ ACW at 24 to 30 m in Primed Subjects

NCT00317109 ·Status: COMPLETED ·Phase: PHASE3